Literature DB >> 15138943

Natural killer cell lymphoma of small intestine with features of enteropathy but lack of association with celiac disease.

Shih-Sung Chuang1, Yun-Chih Jung.   

Abstract

A primary small intestinal natural killer (NK) cell lymphoma with pathologic features of enteropathy but lack of association with celiac disease is reported. A 37-year-old man presented with tarry stool, coffee-ground vomitus, and mild fever. He did not have chronic diarrhea or malabsorption. Segmental resection of the duodenum and jejunum showed multicentric transmural infiltration by medium-sized lymphoma cells expressing CD3, CD8, cytotoxic granules, and Epstein-Barr virus by in situ hybridization. The nontumorous mucosa away from the main tumor revealed enteropathy with villous blunting and increased intraepithelial lymphocytes sharing the same immunophenotype as the lymphoma cells. Both lymphoma and nontumorous areas were germline for T-cell receptor-gamma and immunoglobulin heavy chain gene rearrangement. Serologic test by ELISA was negative for anti-transglutaminase. The patient died of repeated gastrointestinal bleeding and sepsis at 2 months. Differential diagnosis of this unique nasal-type NK-cell lymphoma with enteropathy-associated T-cell lymphoma is discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138943     DOI: 10.1016/j.humpath.2004.01.013

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  2 in total

1.  The first report of a previously undescribed EBV-negative NK-cell lymphoma of the GI tract presenting as chronic diarrhoea with eosinophilia.

Authors:  Ahmad Zaheen; Jan Delabie; Rajkumar Vajpeyi; David W Frost
Journal:  BMJ Case Rep       Date:  2015-11-26

2.  Extranodal NK/T cell lymphoma, nasal type, of the small intestine diagnosed by double-balloon endoscopy.

Authors:  Shihoko Wakabayashi; Ayako Arai; Gaku Oshikawa; Akihiro Araki; Mamoru Watanabe; Naoyuki Uchida; Shuichi Taniguchi; Osamu Miura
Journal:  Int J Hematol       Date:  2009-11-20       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.